Parkinson disease genetics is moving from classification to clinical action
Parkinson disease has never behaved like a single disorder. Its course varies, its treatment response varies, and the underlying biology varies in ways that are now impossible to ignore. Genetic discoveries over the past three decades have reframed the disease as a collection of biologically related syndromes rather than one uniform entity, with rare monogenic forms, strong risk variants, and many common and rare alleles each contributing different degrees of heritability. The clinical consequence is direct: a patient’s genetic profile can now inform how the disease is discussed, how risk is estimated, and how future therapies may be selected.
The most important shift is conceptual. Genetics is no longer just a research tool for rare families; it is becoming a framework for diagnosis, counseling, and therapeutic stratification in routine neurology practice.
From single-gene Parkinson disease to a layered genetic architecture
The review traces how the field moved from the discovery of rare monogenic disease genes to the recognition of a far broader genetic architecture. Early work established that some families carry highly penetrant variants, while later genome-wide association studies identified more than 100 loci linked to Parkinson disease susceptibility. Between those poles sits a large middle ground of common variants with modest effects, which together influence risk, age at onset, and perhaps biological subtype.
This layered architecture helps explain why two people with the same diagnosis may follow very different trajectories. A single pathogenic variant can produce a strong effect in one family, whereas in another patient the overall burden arises from the accumulation of many small-effect alleles. In practice, this means that genetic information is beginning to move beyond the question of whether a person has Parkinson disease and toward the question of which form of Parkinson disease is present.
Biological pathways now anchor the genetic signal
The genetic findings have been most useful when they were translated into pathway biology. Three themes recur across the disease: protein misprocessing, lysosomal dysfunction, and mitochondrial impairment, with altered immune response increasingly recognized as a fourth major axis. These are not abstract labels. They define how neurons fail.
Protein handling defects point to the central problem of abnormal aggregation and clearance, a process closely tied to alpha-synuclein biology. Lysosomal impairment suggests failure of the cell’s disposal machinery, leaving damaged proteins and organelles to accumulate. Mitochondrial dysfunction implicates energy failure and oxidative stress in the vulnerability of dopaminergic neurons. Immune dysregulation adds another layer, consistent with a disease in which inflammation may amplify neurodegeneration rather than merely accompany it.
The value of genetics lies in making these pathways actionable. When a variant identifies a biologically distinct subgroup, it becomes possible to align therapy development with the mechanism most likely to matter in that subgroup.
Genetic information is changing counseling and prognosis
Clinicians are already using genetic information to support decision-making, even before disease-modifying treatments are broadly available. In families with a known pathogenic variant, testing can sharpen counseling about inheritance and recurrence risk. In sporadic cases, increasingly sophisticated interpretation of risk alleles can help frame prognosis and identify people who may be more likely to develop disease or to carry a particular biological subtype.
Polygenic risk scores are especially important here. By aggregating many common variants, they may improve risk prediction beyond any single locus. The review also points to gene-prioritization tools that can help separate likely causal genes from nearby signals and identify new druggable targets. For clinicians, this could eventually mean more informative preclinical risk discussions, more precise phenotyping, and more rational trial enrollment.
Yet penetrance remains incomplete, and expression remains variable. A variant may increase risk without determining fate. This is a major reason why genetic counseling in Parkinson disease still requires careful context, not deterministic language.
Precision medicine in Parkinson disease will depend on stratified trials
The clearest translational value of genetics may lie in drug development. Genetic insights are already enabling targeted strategies and genetically stratified clinical trials, which is a major departure from earlier one-size-fits-all approaches. Instead of testing therapies across a broad heterogeneous population, investigators can enrich for patients whose disease biology matches the intervention.
This matters because a therapy directed at lysosomal dysfunction will not be expected to perform equally well in a subgroup dominated by mitochondrial defects. A trial centered on one pathway may fail if the enrolled population is too mixed. Genetic stratification offers a way to reduce that noise and increase the chance of seeing a true treatment signal.
The review also makes clear why this approach is so attractive in a neurodegenerative disorder with slow progression. Disease-modifying therapy must hit the right biology early enough to matter. Genetics is one of the few tools that can help define that biology before irreversible neuronal loss has advanced too far.
Missing heritability and ancestry gaps still limit interpretation
The genetic story is not complete. Missing heritability remains a major issue, and it is not just a technical problem. It reflects the reality that current models still fail to capture all of the genetic contributors to Parkinson disease, especially across multiple ancestries. If the evidence base is concentrated in particular populations, risk prediction and variant interpretation will be less reliable elsewhere.
That gap has clinical consequences. A score or panel built from one ancestry group may not transfer cleanly to another. Variant frequency, effect size, and pathogenic interpretation can all differ across populations, leaving some patients less well served by current tools. Any push toward precision medicine has to confront that limitation directly if it is to be equitable rather than merely more sophisticated.
The next step is integrating genetics with multiomic biology
The review argues for a multiomic future in which genetic profiling is combined with other biological layers to define novel subtypes of Parkinson disease. That direction is logical. Genetics alone can identify susceptibility and mechanism, but it does not fully capture how a disease behaves in a given patient at a given time. Integrating genomic data with broader molecular and clinical signals could reveal subgroups amenable to targeted disease-modifying interventions.
A patient with Parkinson disease and a particular risk variant may look similar at the bedside to another patient with the same motor phenotype, yet their biology may differ in ways that become clinically relevant once a targeted treatment is available. The practical goal is not simply to label more variants. It is to use those variants to sort patients into groups that can be treated differently, followed differently, and counseled more accurately.
For now, the field is still in transition. Genetic information is already influencing counseling and research design, but routine disease modification remains out of reach. The central challenge is not whether Parkinson disease genetics matters; it does. The real challenge is turning biological insight into therapies that change outcomes in patients whose disease biology is finally being divided into recognizable subtypes.